Actively Recruiting

Phase Not Applicable
Age: 21Years - 65Years
All Genders
ID06344481

A Prospective, Multicenter, Single-Arm, 2-Phase First-in-Human Feasibility Study of the HYALEX Cartilage System

Led by Hyalex Orthopaedics, Inc. · Updated on 2025-06-29

15

Participants Needed

2

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the safety and technical performance of the HYALEX Knee Cartilage System in patients with cartilage injury of the knee femoral condyles who need surgical treatment. This first-in-human, prospective, multicenter, open-label study aims to assess the implant in symptomatic patients aged 21 to 65 years, focusing on areas with specific cartilage damage. The study is divided into two phases to test feasibility and outcomes in different lesion severities and sizes. Participants will receive the Hyalex Cartilage Knee Implant surgically, targeting cartilage and bone loss at the medial or lateral femoral condyles. Phase 1 involves patients with a single lesion, while phase 2 includes those with up to three treatable lesions. The study evaluates implant safety over 24 months and changes in knee function and pain scores over 12 months after implantation. Throughout the study, patients will be monitored for implant rejection, infection, and improvements in knee pain using the Knee Injury & Osteoarthritis Outcome Score (KOOS). Assessments include clinical evaluations and imaging as needed. The trial spans up to two years post-implantation, with regular follow-ups to track safety and technical performance of the device.

CONDITIONS

Brief Title

The Hyalex First-in-Human Study

Who Can Participate

Age: 21Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 21 and 65 years
  • Body Mass Index (BMI) of 35 or less
  • For Phase 1: Single treatable joint surface lesion, ICRS Grade 3 or 4, on medial or lateral femoral condyle
  • For Phase 2: Up to three treatable joint surface lesions, ICRS Grade 3 or 4, on medial or lateral femoral condyles
  • Symptomatic treatable area size between 1 and 3.8 cm2 (Phase 1) or 1 to 10 cm2 (Phase 2)
  • Knee Injury and Osteoarthritis Outcome Score (KOOS) pain subscale score between 20 and 65
  • Stable knee
  • Not improved after at least 3 weeks of conservative treatment including non-steroidal anti-inflammatory drugs and/or physical therapy
Not Eligible

You will not qualify if you...

  • Known allergy to polyurethane, bone cement, acrylic, or titanium
  • Less than 2 mm of healthy cartilage and 2 mm of vital bone wall around the implant site
  • Osteochondral defect deeper than 11 mm from adjacent articular surface
  • Bipolar cartilage lesions involving patellar or tibial lesions opposite the treatment site
  • Insufficient bone stock or bone density preventing implant fit
  • Kellgren and Lawrence grade 3 or 4 on standing X-rays
  • Hip-knee-ankle angle malalignment greater than ±5 degrees
  • Non-functioning opposite knee limiting activity
  • Femoral condyle or tibial plateau insufficiency fracture
  • Recent osteochondritis dissecans within 1 year
  • Other knee injuries interfering with participation or assessment
  • Systemic bone or cartilage disorders like osteoporosis or osteogenesis imperfecta
  • Symptomatic musculoskeletal conditions in lower limbs affecting assessments
  • Tumors in the treatment knee
  • Prior radiation therapy to the knee joint
  • Significant vascular or neurological disorders of lower limbs affecting function
  • Untreated ligament deficiencies or severe ligament instability in study knee
  • Knee surgery within past 6 months except diagnostic arthroscopy, debridement, or meniscectomy
  • Intra-articular injections (hyaluronic acid or steroids) within 3 months before surgery

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Surgery and Immediate Post-operative Care

Duration - Up to several days to weeks as clinically indicated

Participants undergo implantation of the Hyalex Cartilage Knee Implant and receive immediate post-operative care.

1 surgical visit (in-person) and approximately 6 post-operative visits

Post-operative Follow-up

Duration - Up to 24 months

Participants are monitored for implant rejection, infection, and recovery, including assessments of knee function and pain.

Regular visits through 24 months, including assessments at 12 months

Trial Site Locations

Total: 2 locations

1

SPORTO

Lodz, Poland, 09-038

Actively Recruiting

2

LIFE Medical Center

Warsaw, Poland, 00-855

Actively Recruiting

Loading map...

Research Team

C

Chris Cain

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Similar Trials

Therapeutic Effect of Platelet-rich Plasma (PRP) Injection o...

Platelets-rich Plasma

Actively Recruiting

1 location

Clinical Study of Cartilage Constructed by Autologous Bone M...

Cartilage Injury

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here